This article was originally published in The Gray Sheet
Aesthetic and cosmetic laser system maker's secondary offering of 2.43 mil. shares of common stock at $14 per share is outlined in a prospectus filed July 23 with the Securities and Exchange Commission. Of the shares being offered, approximately 1.5 mil. are being sold by the company and about 930,000 are being offered by selling shareholders. Estimated proceeds to Candela of approximately $19.3 mil. will be used for general corporate purposes, including working capital. The Wayland, Massachusetts firm's offering is being managed by Needham & Company and Tucker Anthony Cleary Gull
You may also be interested in...
The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.
Attorneys tell Medtech Insight a recent proposal to review regulations every 10 years could lift some burdens from the medical device industry, but warned that the full effects may not be seen for some time.
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.